Treatment of chronic hepatitis

British Medical Journal

Volumn 323, Issue 7322, 2001, Pages 1164-1167

  Gow, P J ^a   Mutimer, D ^b  

^a AUSTIN HEALTH   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE; MACROGOL; RIBAVIRIN;

CHRONIC HEPATITIS; DRUG EFFICACY; DRUG INDICATION; DRUG MIXTURE; DRUG RESPONSE; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS C; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; RIBAVIRIN;

EID: 0035904599     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. The prevalence of hepatitis B infection in adults in England and Wales
2. Routine antenatal screening for hepatitis B using pooled sera: Validation and review of 10 years experience
3. A one-year trial of lamivudine for chronic hepatitis B
4. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
5. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
6. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine
7. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
8. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up
9. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
10. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
11. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection
12. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: Uptake and acceptability of named antenatal testing
13. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C
14. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
15. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
16. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
17. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients
18. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis